KŘÍŽKOVÁ, Soňa, Michal MASAŘÍK, Petr MAJZLÍK, Jiří KUKAČKA, Jarmila KRUSEOVÁ, Vojtěch ADAM, Richard PRŮŠA, Tomáš ECKSCHLAGER, Marie STIBOROVÁ and René KIZEK. Serum metallothionein in newly diagnosed patients with childhood solid tumours. Acta Biochimica Polonica. Poland, 2010, vol. 57, No 4, p. 561-566. ISSN 0001-527X.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Serum metallothionein in newly diagnosed patients with childhood solid tumours
Authors KŘÍŽKOVÁ, Soňa (203 Czech Republic, belonging to the institution), Michal MASAŘÍK (203 Czech Republic, guarantor), Petr MAJZLÍK (203 Czech Republic), Jiří KUKAČKA (203 Czech Republic), Jarmila KRUSEOVÁ (203 Czech Republic), Vojtěch ADAM (203 Czech Republic, belonging to the institution), Richard PRŮŠA (203 Czech Republic), Tomáš ECKSCHLAGER (203 Czech Republic), Marie STIBOROVÁ (203 Czech Republic, belonging to the institution) and René KIZEK (203 Czech Republic, belonging to the institution).
Edition Acta Biochimica Polonica, Poland, 2010, 0001-527X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10600 1.6 Biological sciences
Country of publisher Poland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 1.234
RIV identification code RIV/00216224:14110/10:00049683
Organization unit Faculty of Medicine
UT WoS 000285726300023
Keywords in English metallothionein; cancer; serum; Brdicka reaction; marker
Tags International impact, Reviewed
Changed by Changed by: Mgr. Michal Petr, učo 65024. Changed: 5/10/2012 15:58.
Abstract
Tumour markers are substances produced by malignant cells or by the organism as a response to cancer development. Determination of their levels can, therefore, be used to monitor the risk, presence and prognosis of a cancer disease or to monitor the therapeutic response or early detection of residual disease.Results found in this work indicate that the MT level in blood serum can be considered as a promising marker for diagnostics, prognosis and estimation of therapy efficiency of childhood tumours.
Abstract (in Czech)
Práce popisuje stanovení nádorových markerů, především metalothioneinu u dětských pacientů se solidními nádory.
Links
GP301/09/P436, research and development projectName: Analýza metalothioneinu u karcinomu prostaty na úrovni DNA, RNA a proteinu.
Investor: Czech Science Foundation
NS10200, research and development projectName: Nádorové markery, jejich stanovení a korelace s karcinomem prostaty
Investor: Ministry of Health of the CR
PrintDisplayed: 18/10/2024 00:52